[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Ifosfamid is an alkylating cytostatic agent which appears to differ in its clinical spectrum from the chemically similar cyclophosphamid. So far, however, its pronounced urotoxicity has limited dosage. In spite of prophylactic measures such as forced diuresis and alkalinization of the urine, the treatment has frequently has to be broken off because of macrohematuria and hemorrhagic cystitis. By repeated intravenous administration of sodium-mercapto-ethan-sulfonate (NNI: Mesnum) the urotoxic side effects of ifosfamid can largely be prevented. During 26 cycles of treatment in 18 patients, asymptomatic microhematuria was observed 6 times and macrohematuria only once in a patient with vesico-vaginal fistula. In another case where therapy had had to be discontinued because of hemorrhagic cystitis in spite of conventional prophylaxis, the treatment could be continued without change in the urine sediment under prophylaxis with Mesnum. Mesnum does not affect the antitumoral activity of ifosfamid.
D000328:Adult; D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D003556:Cystitis / Q000517:prevention & control; D006417:Hematuria / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy
D008623:Mercaptoethanol; D003520:Cyclophosphamide; D015080:Mesna; D007069:Ifosfamide
Hochdosierte Ifosfamidtherapie: systemischer Einsatz eines Mukolytikums zur Verminderung der Urotoxizität.